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ABSTRACT Detectionofmicrobialantigensinclinicalsamplescanleadtorapiddiagnosisofaninfectionandadministrationof
appropriatetherapeutics.Amajorbarrierindiagnosticsdevelopmentisdeterminingwhichofthepotentiallyhundredsorthou-
sandsofantigensproducedbyamicrobeareactuallypresentinpatientsamplesindetectableamountsagainstabackgroundof
innumerable host proteins. In this report, we describe a strategy, termed in vivo microbial antigen discovery (InMAD), that we
usedtoidentifycirculatingbacterialantigens.Thistechniquestartswith“InMADserum,”whichisﬁlteredserumthathasbeen
harvestedfromBALB/cmiceinfectedwithabacterialpathogen.TheInMADserum,whichisfreeofwholebacterialcells,isused
toimmunizesyngeneicBALB/cmice.Theresulting“InMADimmuneserum”containsantibodiesspeciﬁcforthesolublemicro-
bialantigenspresentinserafromtheinfectedmice.TheInMADimmuneserumisthenusedtoprobeblotsofbacteriallysatesor
bacterialproteomearrays.BacterialantigensthatarereactivewiththeInMADimmuneserumarepreciselytheantigenstotar-
getinanantigenimmunoassay.ByemployingInMAD,weidentiﬁedmultiplecirculatingantigensthataresecretedorsheddur-
ing infection using Burkholderia pseudomallei and Francisella tularensis as model organisms. Potential diagnostic targets iden-
tiﬁedbytheInMADapproachincludedbacterialproteins,capsularpolysaccharide,andlipopolysaccharide.TheInMAD
techniquemakesnoassumptionsotherthanimmunogenicityandhasthepotentialtobeabroaddiscoveryplatformtoidentify
diagnostictargetsfrommicrobialpathogens.
IMPORTANCE Effectivetreatmentofmicrobialinfectioniscriticallydependentonearlydiagnosisandidentiﬁcationoftheetio-
logicalagent.Onemeansforrapiddiagnosisisimmunoassayforantigensthatareshedintobodyﬂuidsduringinfection.Immu-
noassayscanbeinexpensive,rapid,andadaptabletoapoint-of-careformat.Amajorimpedimenttoimmunoassayfordiagnosis
ofinfectiousdiseaseisidentiﬁcationofappropriateantigentargets.Thisreportdescribesastrategythatcanbeusedforidentiﬁ-
cation of microbial antigens that are shed into serum during infection by the biothreats Burkholderia pseudomallei and
Francisella tularensis. Termed InMAD (in vivo microbial antigen discovery), the strategy has the potential for application to a
broadspectrumofmicrobialpathogens.
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I
mmunoassay for detection of microbial antigens is a well-
established tool for diagnosis of a wide variety of infectious
diseases. Rapid diagnosis can lead to selection of an appropriate
antimicrobial to treat the infection at an early stage when anti-
biotics are most effective. Early diagnosis and targeted use of
antibiotics may also reduce the development of antibiotic resis-
tance.
A key ﬁrst step in the development of a diagnostic test that
targetsantigenisidentiﬁcationofoneormoremicrobialproducts
that are shed into body ﬂuids during infection. In some cases,
there are obvious choices, e.g., capsular polysaccharides (CPSs).
However,formostmicrobes,thechoiceisnotobvious.Forexam-
ple,whichofthepotentiallyhundredsorthousandsofproteinsor
polysaccharides that are produced by a bacterium or fungus are
actually shed into serum or urine in amounts sufﬁcient for detec-
tion by immunoassay?
Thegoalofthisstudywastodesignastrategyforidentiﬁcation
of potential antigen targets for immunodiagnosis of bacterial in-
fection.Therearethreerequirementsforanidealtargetdiscovery
strategy. First, the technology should make no assumptions re-
garding target structure, synthesis, or secretion. Second, the ap-
proach must identify only those candidate antigens that are actu-
allypresentinthebodyﬂuidthatmightbeadiagnosticspecimen.
Third, targets that are identiﬁed must be immunogenic to allow
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struction.
For this study, we examined the biothreats Burkholderia pseu-
domalleiandFrancisellatularensis,thecausativeagentsofmelioid-
osis and tularemia, respectively. B. pseudomallei and F. tularensis
are facultative intracellular pathogens that can replicate inside
several types of cells (1, 2). Both present diagnostic challenges.
Culture of B. pseudomallei is best accomplished by laboratories in
areasofdiseaseendemicitywithexperienceinisolatingthepatho-
gen.Levelsofbacteremiamaybeverylow(~1CFU/mlblood)(3).
CultureandidentiﬁcationofF.tularensisaredifﬁcult.F.tularensis
isfastidious;isolationisbestdoneusingspecializedmedia,andthe
bacterium grows slowly (4). In both cases, empirical treatment of
an infection that often has nonspeciﬁc symptoms with antibiotics
mayyieldsubsequentclinicalsampleswithnegativecultures.Cul-
ture of both of these pathogens presents potential hazards to lab-
oratorypersonnel.Finally,rapiddiagnosisofbothB.pseudomallei
and F. tularensis infection, perhaps in a point-of-care setting, has
become an important goal due to the potential use of either bac-
terium as an agent of bioterrorism (5).
Our results showed that a novel target identiﬁcation strategy
thatwehavetermedinvivomicrobialantigendiscovery(InMAD)
is a means for identiﬁcation of immunogenic bacterial antigens
that are shed into body ﬂuids during infection. The B. pseudo-
mallei capsular polysaccharide (CPS) is one of several antigens
identiﬁedbyInMADandservesasaproofofprinciple.Following
production of a CPS-speciﬁc monoclonal antibody (MAb), this
antigen was identiﬁed in urine and serum samples from melioid-
osis patients.
RESULTS
IdentiﬁcationofB.pseudomalleiantigensthataresecreteddur-
ing infection. B. pseudomallei was used as a model pathogen to
assess the ability of the InMAD technique to identify bacterial
antigensthatarecirculatinginserumduringinfection(Fig.1).To
begin, BALB/c mice were infected with B. pseudomallei (strain
1026b)bytheintranasalroute.Whenthemicebecamemoribund,
blood was collected and serum was isolated. The serum was ﬁl-
tered to remove whole bacterial cells, leaving secreted/shed anti-
gens behind. This “InMAD serum,” either undiluted or diluted
with phosphate-buffered saline (PBS), was combined with Titer-
Max adjuvant and used to immunize syngeneic BALB/c mice.
“InMAD immune serum” was then collected at various times
postimmunization. By varying the immunization dose and time
for collection of serum, we were able to determine the optimal
amount of InMAD serum for immunization and the time after
immunization that yielded the most immunoreactive serum.
InMAD immune sera were screened for reactivity by probing
Western blots of whole-cell lysates of B. pseudomallei (strain
1026b). InMAD serum diluted 1:2 in adjuvant failed to produce a
stable emulsion. However, InMAD serum diluted 1:2 in PBS, fol-
lowedbytheadditionofanequalvolumeofadjuvant,produceda
stable emulsion and produced a strong antibody response. We
also determined that 8 weeks postimmunization was the optimal
time to harvest InMAD immune serum (data not shown).
Western blots of whole-cell lysates of B. pseudomallei were
probedwithInMADimmuneseruminanefforttoidentifycircu-
lating B. pseudomallei antigens (Fig. 2). Sera obtained from ﬁve
representative mice are shown; in every case, the preimmune se-
rum(Fig.2A,leftlaneofeachmousesample)wasunreactivewith
the B. pseudomallei lysate. The InMAD immune serum was reac-
tivewithmultiplebacterialantigensintheimmunoblots(Fig.2A,
rightlaneofeachmousesample).Therewasconsiderablemouse-
to-mousevariabilityinproductionofantibodiesreactivewithdif-
ferent bacterial antigens.
ProteinaseKtreatmentofthecelllysatewasusedtodetermine
if the InMAD immune serum was reactive with polysaccharides.
InMAD immune serum from a representative mouse is shown.
This serum was reactive with both high-molecular-weight anti-
gens and multiple antigens between 50 and 25 kDa (Fig. 2B, lanes
2 and 3). Upon treatment of the B. pseudomallei lysate with pro-
teinaseK,onlythehigh-molecular-weightantigenremainedreac-
tive (Fig. 2B, lane 4). Similar results were found with sera from
other immunized mice (data not shown).
TheB.pseudomalleicapsularpolysaccharide(CPS)isapossible
candidate for the proteinase K-resistant, high-molecular-weight
antigen recognized by the InMAD immune serum. To further
characterize this high-molecular-weight antigen, a blot prepared
FIG 1 InMAD strategy for identifying secreted/shed bacterial antigens.
BALB/c mice were infected with a pathogen, and InMAD sera were harvested
when mice become moribund. Filtering the InMAD sera removed whole bac-
teria, and secreted/shed bacterial antigens in the sample passed through the
ﬁlter. Syngeneic mice were then immunized with the InMAD sera combined
withadjuvant.InMADimmuneserawereharvestedfromtheimmunizedmice
and used to probe bacterial cell lysates by Western blotting or a bacterial
proteome array.
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InMAD immune serum. The InMAD immune serum was not
reactive with a proteinase K-treated cell lysate prepared from the
CPS mutant, suggesting that CPS is the high-molecular-weight
antigen recognized by the InMAD serum (Fig. 2B, lane 5). In ad-
dition,ﬁveotherInMADimmuneserathatwerereactivewiththe
proteinaseK-insensitive,high-molecular-weightantigensimilarly
werenotreactivewiththeproteinaseK-treatedCPSmutantlysate
(data not shown).
Two-dimensional immunoblotting followed by analysis of
spotsbymassspectrometrywasperformedtoidentifytheB.pseu-
domallei proteins that are recognized by InMAD immune sera.
Twoseparateexperimentswereperformed;ineachcase,aB.pseu-
domallei lysate was probed with InMAD immune sera pooled
from several mice. The preimmune samples were uniformly un-
reactive by Western blotting (examples shown in Fig. 2A). Ta-
ble S1 in the supplemental material summarizes the mass spec-
trometry data; the proteins listed were clearly reactive by two-
dimensional (2-D) immunoblotting. Proteins listed in Table S1
include chaparone GroEL (BPSS0477), F0F1 ATP synthase alpha
(BPSL3398), and elongation factor Tu (BPSL3228).
Conﬁrmationofacandidatediagnostictargetinmelioidosis
clinical samples. The InMAD procedure suggested that CPS is a
circulating B. pseudomallei antigen; therefore, experiments were
done to produce a CPS MAb. Heat-killed B. pseudomallei strain
1026bwasusedtoimmunizeBALB/cmiceaspreviouslydescribed
(7). At least 10 hybridoma clones produced antibodies that were
reactive in Western blots with B. pseu-
domallei whole-cell lysates. Two clones
produced antibodies that were reactive
with high-molecular-weight, proteinase
K-resistant antigens. One clone, 3C5, was
chosen for further study on the basis of a
strong signal by Western blotting and
enzyme-linked immunosorbent assay
(ELISA).
MAb 3C5 was reactive with the high-
molecular-weight, proteinase K-insensitive
antigen identiﬁed via InMAD (Fig. 3A,
lanes Bp and Bp-PK). This MAb was not
reactive with a lysate prepared from the
CPS mutant used in Fig. 2; however, it
was reactive with the B. pseudomallei par-
ent strain from which the mutant was
generated (Fig. 3A, lanes Cap and
Cap). MAb 3C5 was also reactive with
puriﬁed CPS (Fig. 3A, lane CPS), con-
ﬁrming that the proteinase K-resistant
antigenidentiﬁedviaInMADwas,infact,
CPS. MAb 3C5 was not reactive with ly-
sates of Burkholderia thailandensis but
was reactive with Burkholderia mallei ly-
sate, although at a slightly lower molecu-
lar weight than the CPS of B. pseudomallei
(Fig. 3A, lanes Bt and Bm).
During the process of isolating a CPS
MAb,wealsoproducedalipopolysaccha-
ride(LPS)-speciﬁcMAb.LPSisanimmu-
nogenic antigen that is surface exposed;
however, it was not identiﬁed by the
InMAD process (Fig. 2B). We were therefore interested in deter-
mining if the negative LPS InMAD results from the discovery
phase would correlate with an inability of an LPS MAb to detect
LPS in InMAD sera and ﬁltered samples from melioidosis pa-
tients.Ifso,theInMADtechniquemayalsobeusefulinrulingout
an antigen that one would predict to be shed or secreted. The
results(Fig.3)foundtheLPSMAb4C7tobereactivewithprotei-
naseK-insensitivecelllysateantigensthatformedaladderpattern
from 20 to 50 kDa (Fig. 3B, lanes Bp and Bp-PK). MAb 4C7 was
reactive with a lysate of the CPS mutant (Fig. 3B, lane Cap)a s
well as lysates of B. thailandensis and B. mallei (Fig. 3B, lanes Bt
and Bm).
Both MAbs 3C5 and 4C7 were used to probe InMAD sera
collected from the infected BALB/c mice. As predicted by the In-
MAD experiments (Fig. 2), the CPS MAb 3C5 was reactive with
the InMAD sera, and the LPS MAb 4C7 was not (Fig. 3C, lanes 1
and 2, respectively).
Western blots were prepared from serum (n  10) or urine
(n10)samplesfrom20melioidosispatientsandprobedforCPS
and LPS with MAbs 3C5 and 4C7, respectively. The serum sam-
ples were taken on admission from 10 patients who were blood
culture positive for B. pseudomallei; quantitative counts in blood
werenotdetermined.Theurinesamplesweretakenonadmission
from 10 patients whose urine cultures were positive for
B. pseudomallei. All samples were ﬁlter sterilized before analysis.
MAb 4C7 was not able to detect LPS in either serum or urine
samples by Western blotting (data not shown), a result that is
FIG 2 B. pseudomallei proteins and the capsular polysaccharide are reactive with InMAD immune
serum. (A) Five representative InMAD immune serum samples (right lane for each mouse) and pre-
immune serum samples (left lane for each mouse) were used to probe a 1-D immunoblot of a B. pseu-
domallei whole-cell lysate. (B) Serum from a representative mouse was used to determine if reactive
antigenswerepolysaccharidesorproteins.Preimmuneserum(lane1)isnotreactivewitha1-Dblotof
a B. pseudomallei whole-cell lysate. InMAD immune serum from the same mouse is reactive with
multiple antigens (lane 2; lane 3 is a longer exposure). Only the high-molecular-weight antigen is
reactive when InMAD immune serum is used to probe a blot of a proteinase K-treated lysate (lane 4).
ThesameInMADimmuneserumisnotreactivewithaproteinaseK-treatedlysatefromB.pseudomallei
CPS mutant strain SR1015 (lane 5). Antibody detection was done with a goat anti-mouse IgG-HRPO
second antibody.
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sera from infected mice (Fig. 3). The CPS MAb 3C5 was not reac-
tive when used to probe Western blots of patient sera. However,
MAb 3C5 was reactive by Western blotting for CPS in urine sam-
ples containing greater than 100,000 CFU/ml (prior to ﬁltration)
(Fig. 4). Weaker reactivity was seen in a urine sample that con-
tained an estimated 75,000 CFU/ml (Fig. 4, sample UID3). Six
additional urine samples that contained less than 75,000 CFU/ml
(including sample UID1) (Fig. 4) were negative by Western blot-
ting (data not shown).
MAbs 3C5 and 4C7 were used to develop antigen capture
ELISAs for detection of CPS and LPS antigens in melioidosis
patient samples. Unlabeled MAbs were used in the capture
(solid) phase of an ELISA plate, and horseradish peroxidase
(HRPO)-labeledMAbswereusedasindicators.MAb4C7wasnot
able to detect LPS in patient serum or urine samples by capture
ELISA (data not shown). However, CPS MAb 3C5 was reactive
withserumandurinesamplesobtainedfrommelioidosispatients
by ELISA (Fig. 5). Five of the ten serum samples tested were pos-
itive (Fig. 5, left). In addition, MAb 3C5 was highly reactive by
ELISA with CPS in six of ten urine samples (Fig. 5, right). Titers
were recorded as the highest dilutions that produced positive sig-
nals (optical density at 450 nm [OD450]  0.5) and are listed in
Table 1.
Identiﬁcation of F. tularensis antigens that are secreted dur-
ing infection. The ability of the InMAD technique to identify
antigens that are shed during infection was conﬁrmed with a
mouse model of tularemia. Similar to the B. pseudomallei study,
sera harvested from mice infected with F. tularensis were ﬁltered
and used to immunize BALB/c mice. The reactivity of InMAD
immune sera harvested from ﬁve individual mice is shown in
Fig. 6A (lanes 1 to 5). A number of F. tularensis antigens were
reactive with the immune sera. A high-molecular-weight (250-
kDa) antigen recognized by serum from mouse 1 was sensitive to
treatment with proteinase K (Fig. 6B). The InMAD immune se-
rum from mouse 4 (Fig. 6A, lane 4) was reactive in a “ladder”
pattern similar to that produced by F. tularensis LPS (8, 9). The
putative LPS reactivity was conﬁrmed by probing a proteinase
K-treated lysate with InMAD immune serum from mouse 4
(Fig.6C,lane8)andcomparingthispatternofreactivitywiththat
producedbyprobingwithMAbFB11,anF.tularensisLPS-speciﬁc
antibody (Fig. 6C, lane 9). Multiple InMAD immune serum sam-
plesfromdifferentmicewerereactivewithLPS(datanotshown).
An F. tularensis proteome array (10) was probed with InMAD
immune serum to identify individual proteins recognized by
theimmuneserum(Fig.6D).Thearraywasfabricatedby(i)PCR
amplifying each F. tularensis open reading frame (ORF),
(ii) in vivo recombination cloning, and (iii) in vitro transcription/
translation and microarray printing. InMAD immune serum
samples from individual mice (and pooled samples) were used to
probe the proteome array. A transcription/translation mixture
that did not contain an F. tularensis ORF (no protein expression)
FIG 3 Characterization of CPS- and LPS-speciﬁc MAbs. Both CPS MAb 3C5 (A) and LPS MAb 4C7 (B) are reactive with B. pseudomallei (lane Bp)- and
proteinase K-treated B. pseudomallei (lane Bp-PK)-treated whole-cell lysates. MAb 3C5 is not reactive with a capsule mutant strain SR1015 (lane Cap) but is
reactive with the parental strain from which the mutant was derived (1026b; lane Cap). MAb 3C5 is also reactive with puriﬁed CPS (lane CPS). MAb 4C7 is
reactive with the CPS mutant strain, and the parental strain and is not reactive with puriﬁed CPS. In addition, MAb 3C5 is not reactive with cell lysates of
B.thailandensis(laneBt),whereasMAb4C7isreactive.BothMAbsarereactivewithB.mallei(laneBm).TheMAbswerealsousedtoprobeﬁlteredInMADserum
(C)harvestedfromamousemodelofmelioidosis;CPSMAb3C5wasreactive(InMADlane1),whereastheLPSMAb4C7wasunreactive(InMADlane2).Lanes
1 and 2 were done with a chamber miniblotter in order to conserve InMAD serum.
FIG 4 Detection of CPS in melioidosis patient urine by Western blotting.
MAb3C5wasusedtoprobe10urinesamplesfrommelioidosispatients(lanes
UID1,-2,-3,-5,and-7)andnormalhumanurine(NHU).Samplesnotshown
were negative by Western blotting. Proteinase K-treated B. pseudomallei cell
lysate(laneBp)wasusedasapositivecontrol.AsummaryoftheWesternblot
data is listed in Table 1.
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signal intensity.
The most reactive antigens are listed in Table S2 in the supple-
mental material; examples include peptidyl-prolyl cis-trans
isomerase (FTT1472), chaperone protein GroEL (FTT1696), and
an outer membrane protein (FTT1747). All of the antigens in
Table S2 were at least three times higher than the background
signalintensity,whichrangedfrom5,000to11,000(dependingon
the speciﬁc array). The top three proteins were 13 times higher
than the background level, and the top 12 proteins were at least 5
times above the background level. Five of the proteins identiﬁed
byprobingofproteomearrayswerealsoidentiﬁedby2-Dimmu-
noblotting and mass spectroscopy analysis (Table S2). Notably,
two proteins identiﬁed by probing of immunoblots were among
the proteins producing the strongest signals with the proteome
arrays (pyruvate dehydrogenase E2 component [FTT1484] and a
hypothetical membrane protein [FTT1778]). None of these pro-
teins were reactive by immunoblotting with sera from naive un-
immunized mice.
DISCUSSION
In this report, we identiﬁed circulating bacterial antigens present
in serum following infection with B. pseudomallei or F. tularensis.
Serafrominfectedanimals(InMADsera)wereusedtoimmunize
syngeneic BALB/c mice. Mice immunized with InMAD sera gen-
eratedapolyclonalantibodyresponsetosolublebacterialantigens
present in the sample.
A B. pseudomallei polysaccharide antigen was identiﬁed by
InMAD.Apolysaccharidecompositionwasinferredfromthean-
tigen’s high molecular weight and its resistance to proteinase K
treatment.MAb3C5producedinresponsetoimmunizationwith
B.pseudomalleiwholecellswasreactivewiththesamepolysaccha-
rideantigenrecognizedbytheInMADimmunesera.Thepolysac-
charide antigen was found to be the CPS, which is an unbranched
homopolymer of 1,3-linked 2-O-acetyl-6-deoxy--D-manno-
heptopyranose residues (11). This conclusion is based on three
lines of evidence. First, the InMAD immune sera and MAb 3C5
failed to react with a B. pseudomallei CPS mutant strain. Second,
MAb 3C5 was reactive by immunoblotting with puriﬁed CPS,
whose structure had been conﬁrmed by nuclear magnetic reso-
nance(NMR)analysis.Finally,MAb3C5isreactivewithlysatesof
B. mallei but not with lysates of B. thailandensis (Fig. 3). The
B. pseudomallei capsular gene cluster is present in both B. pseu-
domalleiandB.mallei;however,thisclusteristruncatedinB.thai-
landensis (12).
FIG 5 Detection of CPS in melioidosis patient serum and urine samples by antigen capture ELISA. For each ELISA, MAb 3C5 was used in the capture phase,
followedbyadditionofserialdilutedpatientserum(1:2startingdilution)andurine(nodilutiontostart)samples.HRPO-labeledMAb3C5wasthenusedinthe
indicator phase to detect captured CPS. The titer of each of the clinical samples is listed in Table 1.
TABLE 1 Analysis of serum and urine samples from melioidosis
patients for CPS by Western blotting and antigen capture ELISA
Patient sample CFUa Western blotb ELISA titerc
Urined
UID1 2.25  104  8
UID2 1  105  1,300
UID3 7.5  104  59
UID4 1.2  104  2.8
UID5 1  105  200
UID6 3.5  103  0
UID7 1  105  550
UID9 1  103  0
UID10 1  103  0
UID12 1  103  0
Serumd
MSID1  16
MSID2  0
MSID3  20
MSID4  9.8
MSID5  0
MSID6  2.5
MSID7  0
MSID8  0
MSID9  4.6
MSID10  0
a Quantitative cultures were done with urine samples, and results are reported as the
number of CFU/ml. Blood cultures (serum) are reported only as positive or negative.
All samples were ﬁltered before analysis for antigen.
b Western blotting was prepared from patient urine or serum and was probed with the
CPS MAb 3C5.
c The ELISA titer is the highest dilution of patient urine or serum that produced an
OD450 of 0.5 in an antigen capture ELISA prepared from MAb 3C5.
d The serum and urine samples were collected from different patients.
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form, MAb 3C5 was found to be reactive with antigen in serum
from an animal model of inhalational melioidosis and serum and
urine samples from melioidosis patients. Detection of capsular
polysaccharidesinbodyﬂuidshasbeenusedasanaidtodiagnose
a variety of bacterial infections. The fact that B. pseudomallei CPS
was identiﬁed by InMAD as a potential diagnostic target for me-
lioidosis provides further evidence of the power of this approach
for target identiﬁcation.
Unlike results with the murine model of tularemia in which
LPS was identiﬁed as a likely diagnostic target (Fig. 6), InMAD
immuneseraderivedfromthemelioidosismodeldidnotproduce
a Western blot with cell lysates suggestive of LPS. Consistent with
this observation, the LPS MAb 4C7 was not reactive (i) with sera
fromB.pseudomallei-infectedmice(Fig.3)or(ii)inimmunoblots
or capture ELISA with serum or urine samples from melioidosis
patients. This result provides an important negative control for
the InMAD process.
Western blotting and antigen capture ELISAs were performed
in an attempt to identify CPS in sera from infected mice (InMAD
sera)andserumandurinesamplesfrommelioidosispatients.CPS
was not detectable by Western blotting of patient sera; however,
the ELISA proved to be more sensitive, showing that half of the
serum samples contained CPS. In addition, ELISA identiﬁed CPS
in over half of the urine samples. The sensitivity of the assay for
diagnosis of melioidosis would likely be enhanced if a more sen-
sitive assay platform was used or if samples, i.e., urine, were con-
centrated prior to analysis. These results demonstrate that an an-
tigen found via the InMAD process can be found in body ﬂuids
beyondserumaloneandprovidesfurtherproofofconceptforthe
discovery strategy. These results are consistent with previous re-
ports of higher levels of bacteria in urine samples than in blood
samples of patients with melioidosis (3).
The present study is the ﬁrst report that a structurally deﬁned
CPS is shed into serum and urine in the course of experimental
and clinical melioidosis. There have been reports of B. pseudo-
mallei antigen secretion in human disease. In one instance, poly-
clonalantibodiesraisedagainstwholecellsrecognizedantigensin
patient urine (13, 14). In a second report, a MAb designated 5F8
recognized B. pseudomallei antigen in culture-positive samples of
sputum, pus, pleural ﬂuid, and urine (15). MAb 5F8 was initially
reported to be reactive with LPS (16), although subsequent re-
ports have shown it to be reactive with a structurally undeﬁned
high-molecular-weightpolysaccharide(17,18),quitelikelyapre-
viouslydescribedexopolysaccharidecomposedof D-galactoseand
Kdo (19, 20).
InadditiontoCPS,theInMADapproachidentiﬁedmanypro-
teins that were shed during infection. Each of these is a potential
diagnostic target. Diagnostics development that targets proteins
willcontinuebyproducingpolyclonalandmonoclonalantibodies
reactive with candidate proteins, followed by immunoassay con-
struction.Thegoalistotargetacombinationofantigens(possibly
CPSandmultipleproteins)inordertoincreasethesensitivityand
speciﬁcity of the immunoassay.
A study of F. tularensis was done to verify that InMAD can
identify circulating antigens from a second bacterium. A full pro-
teome array that was previously used to identify immunodomi-
nantF.tularensisantigensinmice(10,21)wasprobedtoallowfor
rapid identiﬁcation of antigens recognized by InMAD immune
serum. A number of proteins were identiﬁed. Of the ten most
immunogenic antigens identiﬁed in this earlier report, ﬁve were
also identiﬁed by our InMAD technique as antigens that circulate
inserumduringanacuteinfection.LPSfromF.tularensiswasalso
identiﬁed by InMAD as a circulating antigen. These results con-
ﬁrm results from the melioidosis study that both polysaccharide
and protein antigens can be identiﬁed via InMAD.
Elements of the InMAD approach were described in two pre-
viousreports.First,LehmannandReissfoundthatimmunization
ofrabbitswithserumfromanimmunosuppressedrabbitinfected
with Aspergillus fumigatus produced antibody that was reactive
with a single antigenic moiety (22), later found to be A. fumigatus
galactomannan (23). More recently, Homer et al. immunized
BALB/c mice with serum from CB-17 SCID mice that were in-
fectedwiththeparasiteBabesiamicroti(24).Serafromtheimmu-
FIG 6 Detection of secreted/shed F. tularensis antigens by InMAD. Five naive mice were immunized with InMAD serum from F. tularensis-infected mice. (A)
InMAD immune sera was harvested from the ﬁve mice, and each sample was used to probe a whole-cell lysate of F. tularensis by Western blotting (lanes 1 to 5).
(B)InMADimmuneserumfrommouse1(lane1)wasusedtoprobeF.tularensiscelllysatepreparedwithproteinaseK(lane6)andwithout(lane7)todetermine
ifthereactivehigh-molecular-weightantigen(250kDa)wasapolysaccharide.(C)InMADimmuneserumfrommouse4(lane4)wasusedtoprobeproteinase
K-treated F. tularensis lysate (lane 8); this reactivity was identical to the ladder pattern induced by anti-F. tularensis LPS MAb FB11 (lane 9). The Western blots
shownformouse5(lane5)wereperformedwithagradientacrylamidegel,whereastheotherblotswereperformedwitha10%gel.(D)InMADimmuneserum
wasusedtoprobeanF.tularensisproteomearray(representativesectionofthearrayisshown).Thetwobrightspotsontheupperrightportionofthearraywere
spottedwithFTT0403,andthetwospotsnearthecenterofthegridwerespottedwithFTT1043.SpotsoutlinedinyellowdidnotcontainanF.tularensisORFin
the transcription/translation reaction and were used to determine background signal intensity.
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sion library. Our studies build and expand on these initial reports
todescribeapotentiallybroaddiscoveryplatform.First,ourstud-
ies took advantage of the ease of proteomic analysis, the power of
protein microarrays, and the inherent speciﬁcity of hybridoma
technologyintargetdiscovery.Second,wedemonstratedfeasibil-
ityusingtwodistinctpathogens.Third,wedemonstratethatboth
polysaccharide and protein antigens can be identiﬁed in the same
discoveryprocess.Fourth,ourstudiesfoundthatapotentialtarget
identiﬁed by use of sera from infected animals for target identiﬁ-
cation identiﬁed shed antigen in a second body ﬂuid, i.e., urine.
Finally, our studies have moved a potential diagnostic target
(CPS) from discovery to MAb production to validation in an an-
imal model to validation with clinical samples.
This report describes a proof of concept for use of InMAD.
Further improvements in this strategy might allow for identiﬁca-
tion of additional or alternative targets. For example, different
stages of disease or production of disease in immunosuppressed
animals or hosts with different levels of resistance might cause
variation in the circulating antigen pool that is presented to the
immunizedmouse.Forexample,ifonewereinterestedinchronic
melioidosis infection, then a C57BL/6 mouse might be a better
choice than the BALB/c mouse, in which melioidosis follows a
more acute course. In addition, different routes of infection and
harvesting serum at different stages of infection may cause varia-
tioninthecirculatingantigenpool.Asaconsequence,theInMAD
process will require modiﬁcation to suit the pathogenic habit of
individual microbes.
Animal-to-animal variation in the polyclonal antibodies pres-
ent in the InMAD immune serum should also be considered. As
shown in Fig. 2 and 6, there are substantial differences in the
antigens that are reactive with InMAD immune serum from indi-
vidual mice. This inherent variability exists even though the mice
are syngeneic and are immunized with pooled samples from in-
fectedmice.Byincreasingthenumberofmicethatareimmunized
with InMAD serum, we were able to generate a consensus set of
circulatingantigensthatwereidentiﬁedfromamajorityofimmu-
nized mice. In addition, the antibody proﬁle generated by the
immunized mice will presumably be affected by (i) choice of ad-
juvant,(ii)boosting,and(iii)useofanoutbredstrainofmouseto
increase antibody diversity.
Finally,thecurrentstudyusedBALB/cmiceforbothinfection
andimmunization;however,asyngeneicmodelmaynotbeessen-
tialtosuccess.WearecurrentlyutilizingInMADserumgenerated
fromoutbredmiceandguineapigstoidentifycirculatingantigens
from fungal pathogens (25). If the InMAD approach can cross
hostspecieslines,itmaybepossibletousehumanserumorurine
to immunize mice. As a consequence, this method may directly
identify circulating antigens present during human disease.
In summary, the InMAD technique is a powerful discovery
platform to identify circulating immunogenic proteins and poly-
saccharides that are present during microbial infections. Identiﬁ-
cationofsuchtargetsmayassistinthedevelopmentofdiagnostics
thatrelyonantigenimmunoassayforearlydiagnosisofinfection.
Transition of this discovery phase to functional immunoassays
will require optimization of immunoassays for speciﬁc diagnostic
targets. In the case of melioidosis, such optimization may include
enhancing the afﬁnity of MAb 3C5 by phage display and produc-
inganexpandedlibraryofCPS-speciﬁcMAbsinordertoimprove
sensitivity. Modiﬁcation to immunoassay procedures may also
further improve sensitivity. Finally, we will be producing MAbs
reactivewithanexpandedsetofB.pseudomalleiantigens,e.g.,the
proteins shown in Table S1 in the supplemental material, and
utilize diagnostic platforms suitable for rapid point-of-care use,
e.g., the lateral ﬂow immunochromatographic assay.
MATERIALS AND METHODS
Bacterial cultures. B. pseudomallei (1026b) and F. tularensis (SCHU S4)
cultures were grown overnight at 37°C in a shaking incubator in brain
heart infusion broth or Chamberlain’s broth, respectively. The bacterial
cells were collected by sedimentation and resuspended in PBS. The
B. pseudomallei cells were heat inactivated at 80°C for 2.5 h, and F. tular-
ensiswasheatinactivatedat72°Cfor2h.Bothpreparationswerecultured
following inactivation to conﬁrm killing of bacterial cells. Heat-
inactivatedCPSmutantstrainSR1015wasacquiredfromDonaldWoods
(University of Calgary).
Animal models. Murine models of pulmonary melioidosis and tula-
remia were used to generate sera from infected animals. For the melioid-
osis model, BALB/c mice were infected by the intranasal route with
5000CFUofB.pseudomalleistrain1026b.Micebecamemoribundat3to
4dayspostinfection,andbloodwascollectedatthattimebycardiacpunc-
ture. For the tularemia model, BALB/c mice were infected via the intra-
nasal route with 50 CFU of F. tularensis SCHU S4. Four days following
infection, blood was collected by cardiac puncture. Serum samples were
ﬁltered though a 0.22-m ﬁlter to remove whole bacterial cells.
Human samples. Urine and serum samples from patients with
culture-positive melioidosis or negative controls were obtained from
sample archives (no identiﬁable private information supplied) at
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical
Medicine, Mahidol University, Bangkok, Thailand. Culturing of serum
and urine samples and quantitative bacterial counts (urine samples only)
were performed as previously described (3).
Immunization of mice with sera from infected mice. Sera from in-
fected mice (6.2 to 50 l) were brought to a ﬁnal volume of 100 l with
PBS or used undiluted (100 l), mixed with 100 l TiterMax gold adju-
vant (TiterMax USA, Inc.), and injected into BALB/c mice via the subcu-
taneousroute.Bloodwascollectedat4,6,8,10,and12weekspostimmu-
nization by retro-orbital bleeding and cardiac puncture. This study was
carriedoutinaccordancewiththerecommendationsintheGuideforthe
Care and Use of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Institutional Animal Care and Use
Committee of the University of Nevada, Reno.
Western blot analysis. A standard Western blot procedure was done
using semidry blotting (MAb 4C7) or tank blotting (InMAD immune
serum or MAb 3C5). Brieﬂy, 8  106 heat-inactivated bacterial cells were
suspendedinLaemmlisamplebuffer(Sigma)andincubatedfor10minat
100°C. If required, 1 volume of a proteinase K solution (3.3 mg in 1 ml
Laemmlisamplebuffer)wasadded,andthesamplewasfurtherincubated
f o r1ha t60°C. In the case of human serum or urine, the sample (20 l)
was mixed with 6 Laemmli sample buffer and treated as described
above. Samples were run on either a 10 to 20% SDS gradient gel or a 10%
SDS gel, followed by transfer onto a polyvinylidene diﬂuoride (PVDF)
membrane.MAbs4C7and3C5werelabeledwithhorseradishperoxidase
(EZ-Link Plus activated peroxidase kit; Pierce) to yield a product at ap-
proximately 0.8 mg/ml and used at a dilution of 1:10,000; signal was
detectedwithachemiluminescentsubstrate(Pierce).MAbFB11(Abcam)
speciﬁc for F. tularensis LPS was used at a 1:100,000 dilution (2 mg/ml
stock). InMAD immune serum was used at a dilution of 1:30. MAb FB11
and mouse antibodies within the InMAD serum were detected with a
horseradish peroxidase-labeled anti-mouse antibody (1:10,000 dilution).
Proteomic analysis. Heat-killed B. pseudomallei cells were lysed and
separated by 2-D gel electrophoresis. Two duplicate gels were produced;
one gel was blotted onto nitrocellulose. InMAD immune serum was used
to probe the membrane, reactive spots were cut from the duplicate gel,
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have been included in Text S1 in the supplemental material.
F. tularensis proteome array. Protein microarray fabrication and
probing methods have been described previously (10). Probing methods
were modiﬁed slightly in that InMAD immune serum used to probe the
proteome array ranged from 1:10 to 1:100 dilutions.
ProductionofMAbs.ProductionofMAbs4C7(LPS)and3C5(CPS)
began with immunization of BALB/c mice with heat-inactivated B. pseu-
domallei (strain 1026b). An intraperitoneal injection of 2  108 bacteria
wasadministeredevery2weeksforan8-weekperiod(7).AnELISA,with
heat-inactivated B. pseudomallei strain 1026b in the solid phase, was used
toassessantibodylevels(7).Threedayspriortoharvestingofspleens,one
ﬁnal intraperitoneal immunization with 2  108 bacteria was adminis-
tered.Hybridomacellswereproducedaspreviouslydescribed(26).West-
ern blot analysis was done to identify hybridoma cell lines that were pro-
ducing anti-LPS (ladder pattern) or anti-CPS (high-molecular-weight,
proteinase K-insensitive) MAbs. Hybridoma cell lines were grown in
Integra CL 1000 culture ﬂasks (Integra Biosciences), and MAbs were pu-
riﬁed by afﬁnity chromatography over a protein A column.
Antigen capture immunoassay for CPS and LPS. Microtiter plates
were coated overnight with either MAb 3C5 or 4C7 at 2 g/ml in PBS,
washed with PBS-Tween (PBS containing 0.5% Tween 20), and blocked
by incubation for an additional 90 min with PBS-Tween. Serial dilutions
of serum, urine, or B. pseudomallei lysate were prepared in PBS-Tween
and incubated for 90 min at room temperature with the MAb-coated
wells.ThewellswerewashedwithPBS-Tween,incubatedfor90minwith
HRPO-labeled MAb 3C5 or 4C7 (2 g/ml), washed, and incubated with
tetramethylbenzidine substrate (Kirkegaard & Perry Laboratories).
CPS puriﬁcation. CPS was puriﬁed essentially as previously de-
scribed (27) using an O antigen-deﬁcient derivative of B. pseudomallei
strain DD503. CPS isolated by this method was conﬁrmed by NMR anal-
ysis to be a polymer of 1,3-linked 2-O-acetyl-6-deoxy--D-manno-
heptopyranose residues (P. J. Brett, unpublished data).
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